Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required

The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults.

Through the support of collaborative,

credit: sun-sentinel


efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Related Programs

Food and Drug Administration_Research

Department of Health and Human Services


Agency: Department of Health and Human Services

Office: Food and Drug Administration

Estimated Funding: $900,000


Relevant Nonprofit Program Categories





Obtain Full Opportunity Text:
RFA-FD-25-001 Funding Opportunity Announcement

Additional Information of Eligibility:
See Eligibility Information on page 12 of the attached solicitation document.

Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-001.html

Contact:


Agency Email Description:
terrin.brown@fda.hhs.gov

Agency Email:


Date Posted:
2024-08-23

Application Due Date:


Archive Date:
2025-11-20



Social Entrepreneurship
Spotlight



Rwanda as Social Entrepreneur Fund Beneficiary


The Republic of Rwanda has been picked as one of the six African countries as beneficiaries for a new fellowship fund program designed at supporting social entrepreneurs in tackling issues on food security.






More Federal Domestic Assistance Programs


Grants to Reduce Domestic Violence, Dating Violence, Sexual Assault, and Stalking on Campus | PPHF 2013 Cooperative Agreement to Support Navigators in Federally-facilitated and State Partnership | Empowerment Zones Program | Perishable Agricultural Commodities Act | International Forestry Programs |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2024 Copyright Michael Saunders